Cover Image
Market Research Report
Product code 
1074127

Global Neurocutaneous Syndrome Market - 2022-2029

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Neurocutaneous Syndrome Market - 2022-2029
Published: May 7, 2022
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market Overview

The global neurocutaneous syndrome market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Neurocutaneous syndromes are disorders that affect the brain, spinal cord, organs, skin, and bones. The diseases are lifelong conditions that can cause tumors to grow in these areas. They can also cause other problems such as hearing loss, seizures, and developmental problems. Each disorder has different symptoms.

Market Dynamics

Advancement in Clinical Testing for the diagnosis of tuberous sclerosis is expected to drive market growth.

TSC is an autosomal dominant hereditary condition characterized by widespread involvement and a wide range of manifestations throughout a person's life. However, genetic testing as an independent criterion may aid in the early diagnosis of affected individuals who lack sufficient clinical diagnostic features. The brain and skin are the most often damaged organ systems in TSC patients, accounting for more than 90 percent of all TSC cases. Moreover, the use of mTORC1 inhibitors, which target the signaling pathway triggered in TSC tumors due to the loss of function of the hamartin-tuberin complex and affect all lesions with TSC, has also affected all lesions had a substantial impact on patient therapy. These novel TSC medicinal drugs necessitated the development of a new treatment method, specifically a cross-sectional medical examination approach. These systems are being put in place all across the world. In addition, a topical sirolimus formulation for skin lesions with TSC has been developed to prevent side effects associated with systemic treatment with mTORC1 inhibitors. More study and experiments will be required to employ these technologies and systems more successfully. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

The lack of awareness in developing countries, stringent regulations, shortage of diagnostic facilities and side effects caused by the drugs are some factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Infections with viruses have a negative impact on neurological processes and can result in serious neurological impairment. Coronaviruses (CoV), particularly the severe acute respiratory syndrome CoV 2 (SARS-CoV-2), have recently been neurotropic capabilities and may induce neurological disorders. According to reports, CoV has been detected in the brain and CSF fluid. Moreover, Outpatient clinics for non-urgent patients were shut down. It became a priority to treat hundreds of frail neurological patients who suddenly had fewer points of reference and Outpatient telemedicine clinics approved by hospital directives. Prescription, booking, consenting, privacy and data security, secure connection with patients (Teams Microsoft 365), electronic report preparation and delivery, reporting, and service accountability were all part of the package.

Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market.

Segment Analysis

Neurofibromatosis (NF) segment is expected to hold the largest market share in neurocutaneous syndrome market

The neurofibromatosis (NF) segment is expected to dominate in 2020. Neurofibromatosis (NF) are of two types Neurofibromatosis Type 1 (NF1) and Neurofibromatosis Type 2 (NF2). In this, Neurofibromatosis Type 1 (NF1) is the most frequent kind of neurofibromatosis, also called Von Recklinghausen's disease. The classic symptom of NF1 is light brown patches of pigment on the skin. These are known as cafe-au-lait spots. A child's skin tumors may or may not be cancerous (benign). Neurofibromas are the medical term for these tumors. Neurofibromas are benign tumors that form on nerves and in organs. People with NF have an increased risk of developing brain tumors. In persons with NF1, less than 1 in 100 will develop cancer (malignant) in their neurofibromas. Lisch nodules can also be found in older children. On the colored area of the eye, these are tiny tumors (iris). Hearing loss, headaches, convulsions, scoliosis, and facial discomfort or numbness are possible symptoms. People with NF1 may be slightly more likely to have an intellectual disability of varying degrees. Approximately half of the students may have a range of learning difficulties and attention deficit disorder. NF1 can cause renal artery stenosis and other vascular issues. Laser therapy effectively treats cafe-au-lait spots, and Neurofibromas are managed by surgical excision. Recurrence is common in both cases. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global neurocutaneous syndrome market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of the rare genetic disorder, improved health care infrastructure, increasing awareness regarding genetic disorders, and high government funding for the healthcare sector in the region are some of the factors the market is expected to boost in the forecast period. For instance, According to the National Institutes of Health (NIH), approximately 7,000 rare diseases affect between 25 and 30 million Americans. This equates to 1 in 10 Americans, one on every elevator and four on every bus. Tuberous sclerosis is a rare genetic disorder that affects 1 in 6,000 newborns in the United States. Approximately 40,000 to 80,000 people in the United States have tuberous sclerosis. Moreover, there are 7,000 known rare diseases, approximately 95 percent have no treatment.

Moreover, The National Organization for Rare Disorders (NORD) is a non-profit organization in the United States that advocates for and funds research, education, and networking among service providers to help people with rare diseases. Therefore, it has increased the demand for treatment for rare genetic disorders. Thus, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the neurocutaneous syndrome market are Novartis Pharmaceuticals Corporation, Pfizer Inc., Greenwich Biosciences, Inc., Fresenius Kabi USA, Lundbeck, Astellas Pharma US, Inc., Endo Pharmaceuticals Inc., Merck & Co., Inc., Genzyme Corporation and GlaxoSmithKline.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its medicines and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

RAPAMUNE (sirolimus): Sirolimus could control the occurrence of epilepsy and improve the appearance, with minor and tolerable adverse reactions. It is especially suitable for patients with severe epilepsy, failure, or contraindications of antiepileptic drugs; it could be an alternative method for patients who are unwilling to accept the risks of neurosurgery.

Why Purchase the Report?

Visualize the composition of the neurocutaneous syndrome market segmentation by type, diagnosis, treatment, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in neurocutaneous syndrome market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of neurocutaneous syndrome market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global neurocutaneous syndrome market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Product Code: DMPH4909

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by Diagnosis
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancement in Clinical Testing for the diagnosis of tuberous sclerosis is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The lack of awareness in developing countries, stringent regulations is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Tuberous Sclerosis (TS)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Neurofibromatosis (NF)
  • 7.4. Sturge-Weber Syndrome
  • 7.5. Von Hippel-Lindau Disease (VHL)
  • 7.6. Ataxia-Telangiectasia (A-T)
  • 7.7. Others

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 8.2. Genetic tests*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. MRI
  • 8.4. CT scan
  • 8.5. Electroencephalogram (EEG)
  • 8.6. Eye exam
  • 8.7. Biopsy
  • 8.8. Others

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment Segment
  • 9.2. Laser therapy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Surgical Procedures
  • 9.4. Cryotherapy
  • 9.5. Medications
    • 9.5.1. TAFINLAR (dabrafenib) + MEKINIST (trametinib)
    • 9.5.2. RAPAMUNE (sirolimus)
    • 9.5.3. EPIDIOLEX (cannabidiol)
    • 9.5.4. Diprivan (Propofol)
    • 9.5.5. SABRIL (vigabatrin)
    • 9.5.6. PROGRAF(tacrolimus)
    • 9.5.7. JANUVIA (sitagliptin)
    • 9.5.8. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals And Clinics*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Ambulatory Surgical Center
  • 10.4. Diagnostic Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Novartis Pharmaceuticals Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Pfizer Inc.
  • 13.3. Greenwich Biosciences, Inc.
  • 13.4. Fresenius Kabi USA
  • 13.5. Lundbeck
  • 13.6. Astellas Pharma US, Inc.
  • 13.7. Endo Pharmaceuticals Inc.
  • 13.8. Merck & Co., Inc.
  • 13.9. Genzyme Corporation
  • 13.10. GlaxoSmithKline

LIST NOT EXHAUSTIVE

14. Global Neurocutaneous Syndrome Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us